The Identification of a CD47-blocking “Hotspot” and Design of a CD47/PD-L1 Dual-Specific Antibody With Limited Hemagglutination

Signal Transduction and Targeted Therapy - United Kingdom
doi 10.1038/s41392-020-0121-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

MYC Promotes Tumorigenesis via Activation of CD47 and PD-L1

Cancer Discovery
Oncology
2016English

A CD47-blocking TRAIL Fusion Protein With Dual Pro-Phagocytic and Pro-Apoptotic Anticancer Activity

British Journal of Haematology
Hematology
2013English

Elimination of Tumor by CD47/PD-L1 Dual-Targeting Fusion Protein That Engages Innate and Adaptive Immune Responses

mAbs
AllergyImmunology
2017English

164 Increased PD-L1 and CD47 Expression in High-Risk Cutaneous Squamous Cell Carcinomas

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

CD47-blocking Antibodies Restore Phagocytosis and Prevent Atherosclerosis

Nature
Multidisciplinary
2016English

Targeting a Membrane-Proximal Epitope on Mesothelin Increases the Tumoricidal Activity of a Bispecific Antibody Blocking CD47 on Mesothelin-Positive Tumors

mAbs
AllergyImmunology
2020English

Tuning the Radio With CD47

Science-Business eXchange
2009English

TMIC-04. A POTENT MICROGLIAL RESPONSE TO BLOCKING THE CD47-SIRPα ANTI-PHAGOCYTIC AXIS OVERCOMES DEFICIENT MACROPHAGE RECRUITMENT DURING ANTI-CD47 IMMUNOTHERAPY AGAINST GLIOBLASTOMA

Neuro-Oncology
Cancer ResearchOncologyNeurology
2017English

Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy